The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind

Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer’s disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer’s disease research in the future.

[1]  C. Duyckaerts,et al.  Large amounts of neocortical βA4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person , 1990, Neuroscience Letters.

[2]  Peter Davies,et al.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.

[3]  G. Howell,et al.  Toward more predictive genetic mouse models of Alzheimer's disease , 2016, Brain Research Bulletin.

[4]  J. Streffer,et al.  Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.

[5]  Natalia L. Komarova,et al.  High Degree of Heterogeneity in Alzheimer's Disease Progression Patterns , 2011, PLoS Comput. Biol..

[6]  S. DeKosky,et al.  Amyloid Imaging with PET in Alzheimer’s Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects , 2009 .

[7]  A. Ebrahimi,et al.  Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease , 2013, Ageing Research Reviews.

[8]  B. Strooper,et al.  BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease , 2016, Trends in Neurosciences.

[9]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[10]  S. Stahl.  Amyloid Cascade Hypothesis of Alzheimer's Disease , 1997 .

[11]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[13]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[14]  C. Lanni,et al.  Dual Effect of Beta-Amyloid on α7 and α4β2 Nicotinic Receptors Controlling the Release of Glutamate, Aspartate and GABA in Rat Hippocampus , 2012, PloS one.

[15]  T. Ohm,et al.  Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology , 2004, Neurobiology of Aging.

[16]  U. Müller,et al.  Functions of the APP gene family in the nervous system: insights from mouse models , 2011, Experimental Brain Research.

[17]  C. Peers,et al.  The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons , 2003, The Journal of Neuroscience.

[18]  E. Fedele,et al.  Cyclic adenosine monophosphate as an endogenous modulator of the amyloid‐β precursor protein metabolism , 2013, IUBMB life.

[19]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[20]  T. Comery,et al.  Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease , 2009, Journal of Pharmacology and Experimental Therapeutics.

[21]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[22]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[23]  C. Alzheimer,et al.  BACE1 modulates gating of KCNQ1 (Kv7.1) and cardiac delayed rectifier KCNQ1/KCNE1 (IKs). , 2015, Journal of molecular and cellular cardiology.

[24]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[25]  R. Morris,et al.  BACE1 gene deletion: Impact on behavioral function in a model of Alzheimer's disease , 2008, Neurobiology of Aging.

[26]  B. Hyman,et al.  The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease , 2007, Neuroscience Letters.

[27]  J. Macor,et al.  Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. , 2010, ACS medicinal chemistry letters.

[28]  S. Ovsepian,et al.  Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions , 2015, Biological Psychiatry.

[29]  Julie S. Snowden,et al.  Variability in cognitive presentation of Alzheimer's disease , 2008, Cortex.

[30]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[31]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[32]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[33]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[34]  S. Kügler,et al.  Alzheimer's disease: old problem, new views from transgenic and viral models. , 2010, Biochimica et biophysica acta.

[35]  Hui Zheng,et al.  Physiological functions of APP family proteins. , 2012, Cold Spring Harbor perspectives in medicine.

[36]  E. Siemers,et al.  Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[37]  Judianne Davis,et al.  Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.

[38]  G. Dawson,et al.  Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein , 1999, Neuroscience.

[39]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[40]  N. Mercuri,et al.  Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease , 2013, Drug design, development and therapy.

[41]  A. Palmeri,et al.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. , 2014, Biochemical pharmacology.

[42]  Huaxi Xu,et al.  The γ-secretase complex: from structure to function , 2014, Front. Cell. Neurosci..

[43]  G. Collingridge,et al.  Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein , 1999, Neuropharmacology.

[44]  P. Mehta,et al.  Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. , 2005, Neuro-degenerative diseases.

[45]  I. Ferrer,et al.  Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice , 2005, Neurobiology of Disease.

[46]  C. Alberini,et al.  Amyloid beta mediates memory formation. , 2009, Learning & memory.

[47]  V. Laporte,et al.  Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. , 2012, The American journal of pathology.

[48]  A. Palmeri,et al.  Endogenous amyloid‐β is necessary for hippocampal synaptic plasticity and memory , 2011, Annals of neurology.

[49]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[50]  H. Cai,et al.  BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions , 2005, The Journal of Neuroscience.

[51]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[52]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[53]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[54]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[55]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  E. Fedele,et al.  A novel mechanism for cyclic adenosine monophosphate–mediated memory formation: Role of amyloid beta , 2014, Annals of neurology.

[57]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[58]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[59]  G. Bloom.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.

[60]  P. Wong,et al.  BACE1 Knock-Outs Display Deficits in Activity-Dependent Potentiation of Synaptic Transmission at Mossy Fiber to CA3 Synapses in the Hippocampus , 2008, The Journal of Neuroscience.

[61]  F. Barkhof,et al.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.

[62]  B. Hyman,et al.  Alzheimer's disease: synapses gone cold , 2011, Molecular Neurodegeneration.

[63]  Nick C Fox,et al.  Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[64]  Feng Wang,et al.  BMS-708,163 targets presenilin and lacks notch-sparing activity. , 2012, Biochemistry.

[65]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[66]  N. Hooper,et al.  A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis * , 2016, The Journal of Biological Chemistry.

[67]  Kenjiro Ono,et al.  Structure–neurotoxicity relationships of amyloid β-protein oligomers , 2009, Proceedings of the National Academy of Sciences.

[68]  B. Winblad,et al.  Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[69]  R. Sperling,et al.  Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[70]  P. Ince,et al.  Review: Astrocytes in Alzheimer's disease and other age‐associated dementias: a supporting player with a central role , 2017, Neuropathology and applied neurobiology.

[71]  E. Fedele,et al.  Amyloid β: Walking on the dark side of the moon , 2015, Mechanisms of Ageing and Development.

[72]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[73]  The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease , 2014, Molecular Neurobiology.

[74]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[75]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[76]  S. Ferreira,et al.  Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease , 2015, Front. Cell. Neurosci..

[77]  Alonso Emilio,et al.  β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment , 2012, EMBO molecular medicine.

[78]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[79]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[80]  E. Fedele,et al.  Evaluating the role of hnRNP-C and FMRP in the cAMP-induced APP metabolism. , 2015, BioFactors.

[81]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[82]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[83]  Nick C Fox,et al.  Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.

[84]  S. Kügler,et al.  AAV-Tau Mediates Pyramidal Neurodegeneration by Cell-Cycle Re-Entry without Neurofibrillary Tangle Formation in Wild-Type Mice , 2009, PloS one.

[85]  John Seibyl,et al.  Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. , 2015, JAMA neurology.

[86]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[87]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[88]  R. Luna,et al.  Amyloid Beta: Multiple Mechanisms of Toxicity and Only Some Protective Effects? , 2014, Oxidative medicine and cellular longevity.

[89]  J. Growdon,et al.  Transmission and age‐at‐onset patterns in familial Alzheimer's disease , 1990, Neurology.

[90]  R. Anwyl,et al.  beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. , 1995, European journal of pharmacology.

[91]  Alicia R. Desilets,et al.  Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease , 2011, The Annals of pharmacotherapy.

[92]  W. Klein,et al.  Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[94]  T. Fülöp,et al.  Anti-Viral Properties of Amyloid-β Peptides. , 2016, Journal of Alzheimer's disease : JAD.

[95]  T. Wisniewski,et al.  Alzheimer’s disease: experimental models and reality , 2017, Acta Neuropathologica.

[96]  W. Klein,et al.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[97]  K. Nave,et al.  Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles , 2013, The EMBO journal.

[98]  R. Tanzi,et al.  Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease , 2016, Science Translational Medicine.

[99]  N. Nalivaeva,et al.  The amyloid precursor protein: A biochemical enigma in brain development, function and disease , 2013, FEBS letters.

[100]  H. Loetscher,et al.  Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.

[101]  M. Tiwari,et al.  β-Amyloid pathogenesis: Chemical properties versus cellular levels , 2016, Alzheimer's & Dementia.